Celyad Oncology Announces FDA Clearance of IND Application for CYAD-211, First shRNA-based, Non-Gene Edited Allogeneic CAR T Therapy https://www.businesswire.com/news/home/20200713005564/en/Celyad-Oncology-Announces-FDA-Clearance-IND-Application https://www.businesswire.com/news/home/20200713005564/en/Celyad-Oncology-Announces-FDA-Clearance-IND-Application